NMN supplementation

NMN reliably does the one thing it is mechanistically supposed to do: multiple placebo-controlled human trials show oral NMN raises circulating NAD+ concentrations dose-dependently and is safe and well tolerated at doses up to 900mg daily. Beyond that, the evidence thins out sharply. Small randomised trials report scattered functional signals: improved walking distance at 30 and 60 days, increased muscle insulin sensitivity in prediabetic women (Yoshino 2021), enhanced aerobic capacity in amateur runners (Liao 2021), and maintained walking speed with improved sleep quality in older adults (Morifuji 2024). These are individually small, short, largely unreplicated, and conducted in heterogeneous populations. Critically, no trial has measured a longevity or a composite healthspan endpoint, and no trial has demonstrated that raising NAD+ produces the downstream ageing benefits the mechanism predicts. The bulk of the compelling ageing-reversal data remains in mice. Singapore's own Centre for Healthy Longevity (Prof. Brian Kennedy and Prof. Andrea Maier, NUHS) has explicitly framed its NMN work around the still-open question of whether supplementation is needed at all in a given individual and what dose makes the NAD+ change clinically meaningful, which is a fair statement of where the field actually sits. Chi Longevity's own copy concedes that "clinical outcomes vary significantly between individuals" and that "generalised supplementation might not produce beneficial results". Intravenous NMN and NAD+ drips rest on a materially weaker footing again: there is no meaningful controlled human outcome evidence for the IV route, and the pharmacokinetic rationale for bypassing oral dosing is not established. Treat oral NMN as a well-characterised NAD+-raising agent in search of a demonstrated clinical benefit, and the drip form as commercial.

What it is

Plain-language explainer

Categories

Common questions

What is NMN supplementation?

NMN reliably does the one thing it is mechanistically supposed to do: multiple placebo-controlled human trials show oral NMN raises circulating NAD+ concentrations dose-dependently and is safe and well tolerated at doses up to 900mg daily. Beyond that, the evidence thins out sharply. Small randomised trials report scattered functional signals: improved walking distance at 30 and 60 days, increased muscle insulin sensitivity in prediabetic women (Yoshino 2021), enhanced aerobic capacity in amateur runners (Liao 2021), and maintained walking speed with improved sleep quality in older adults (Morifuji 2024). These are individually small, short, largely unreplicated, and conducted in heterogeneous populations. Critically, no trial has measured a longevity or a composite healthspan endpoint, and no trial has demonstrated that raising NAD+ produces the downstream ageing benefits the mechanism predicts. The bulk of the compelling ageing-reversal data remains in mice. Singapore's own Centre for Healthy Longevity (Prof. Brian Kennedy and Prof. Andrea Maier, NUHS) has explicitly framed its NMN work around the still-open question of whether supplementation is needed at all in a given individual and what dose makes the NAD+ change clinically meaningful, which is a fair statement of where the field actually sits. Chi Longevity's own copy concedes that "clinical outcomes vary significantly between individuals" and that "generalised supplementation might not produce beneficial results". Intravenous NMN and NAD+ drips rest on a materially weaker footing again: there is no meaningful controlled human outcome evidence for the IV route, and the pharmacokinetic rationale for bypassing oral dosing is not established. Treat oral NMN as a well-characterised NAD+-raising agent in search of a demonstrated clinical benefit, and the drip form as commercial.

How strong is the evidence for NMN supplementation?

Mechanism only. The biological rationale is described, but human outcome data is not established.

Is NMN supplementation approved in Singapore?

Health Sciences Authority position on record: Not evaluated or approved by HSA for any indication. Oral NMN is sold in Singapore under HSA's health supplements framework, which imposes no pre-market approval or licensing requirement for importation, manufacture or sale. Dealers self-assess and self-certify that products meet safety, quality and labelling standards, and HSA notification is voluntary. Health supplements must not be labelled, advertised or promoted for any medicinal purpose, including any claim to treat or prevent disease. Chi Longevity carries the corresponding disclaimer that the supplement "has not been evaluated by the HSA for the purpose of diagnosing, treating, curing or preventing any disease". Intravenous NMN and NAD+ preparations sit outside the supplement regime and are a separate and less clear matter: Artisan Regenerative Centre's own page states that the NAD+ preparation it uses "has not yet been recognized in pharmaceutical and medical device laws". No HSA registration of an injectable NMN or NAD+ therapeutic product was verified.. An evidence grade and a regulatory approval are different questions.

Is NMN supplementation approved in Australia?

Therapeutic Goods Administration position on record: As of 10 December 2025, nicotinamide mononucleotide is a permissible ingredient under the Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025, meaning it may be used in AUST L listed medicines sold in Australia. The TGA has also published a compositional guideline for NMN setting identity, assay, impurity and microbiological standards. This is a reversal of the prior position, under which NMN could be manufactured in Australia only for export and its domestic status was contested. Important limits: permissible-ingredient status is an ingredient approval, not approval of a medicine for a named indication. Listed medicines containing NMN remain confined to low-level general health claims (for example supporting energy production or general wellbeing) and cannot claim to treat, prevent or cure disease, and cannot make longevity or anti-ageing claims. This applies to oral products. No TGA approval of an injectable or IV NMN or NAD+ product was verified, and the TGA maintains a separate safety alert page concerning NAD, NAD+, NADH and NMN medicines sold in Australia which could not be retrieved during this research.. An evidence grade and a regulatory approval are different questions.

Which clinics offer NMN supplementation?

2 clinics in the variis directory across Singapore and Australia have NMN supplementation on record. Each is listed on this page with its own sourced profile.

What else is NMN supplementation called?

Also known as Nicotinamide mononucleotide, NMN, beta-nicotinamide mononucleotide, NMN drip, NAD+ precursor supplementation, NMN IV therapy.